| Cat. No. |
Product Name |
Information |
| PC-Ab1004 |
Atezolizumab
|
A humanized monoclonal antibody to programmed death-ligand 1 (PD-L1) that increases immune reactivity to tumor neoantigens and is used as immunotherapy of selected cancers of the bladder and lung. increases immune reactivity to tumor neoantigens and is used as immunotherapy of selected cancers of the bladder and lung. Atezolizumab has been associated with a low rate of serum enzyme elevations during therapy and with uncommon instances of clinically apparent, immune-mediated liver injury.. |
| PC-Ab1003 |
Rituximab
|
The first monoclonal antibody approved for cancer therapy and the first single-agent approved for therapy of lymphoma. It was approved by the FDA for the treatment of patients with relapsed or refractory low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma in 1997.. |
| PC-Ab1002 |
Magrolimab
|
A monoclonal anti-human CD47 antibody by grafting its complementarity determining regions (CDRs) onto a human IgG4 format. |
| PC-Ab1001 |
Blinatumomab
|
Anti-Human CD3 CD19 BsAb (Blinatumomab biosimilar. |
| PC-36159 |
PROTAC-VHL-ligand hydrochloride
|
PROTAC-VHL-ligand is a von Hippel–Lindau (VHL) ligand used for the proteolysis targeting chimeras (PROTACs) method, induces target protein degradation.. |
| PC-35014 |
VHL-alkyne
|
VHL-alkyne is a VHL ligand for PROTAC synthesis.. |
| PC-62218 |
PROTAC-VHL-ligand
|
PROTAC-VHL-ligand is a von Hippel–Lindau (VHL) ligand used for the proteolysis targeting chimeras (PROTACs) method, induces target protein degradation.. |
| PC-60118 |
VHL Ligand 4
|
A VHL ligand for PROTAC.. |
| PC-60117 |
VHL-2
|
A VHL ligand for PROTAC.. |
